search
Back to results

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

Primary Purpose

Peripheral Artery Disease, Severe Intermittent Claudication

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Autologous Stem Cells (CD34+)
Sponsored by
Losordo, Douglas, M.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Artery Disease

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males or females equal to or greater than 21 years old Patients with infra-inguinal atherosclerosis with a stenosis or occlusion of a major vessel in the affected limb(s) of one or more of the following arteries: superficial femoral, popliteal, or one or more infrapopliteal arteries, which is/are non-reconstructable. Patients with symptoms of Severe Intermittent Claudication in at least 1 lower limb persisting for at least 6 months (Rutherford Class 3). Patients who have a diagnosis of Peripheral Arterial Disease (PAD) in at least 1 lower limb secondary to atherosclerosis, for at least 6 months. Exclusion Criteria: Patients who have had successful aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 3 month preceding screening. Patients with iliac disease amenable to revascularization. Patients judged to be a suitable candidate for surgical or percutaneous revascularization in the limb in which treatment is proposed. Patients with Critical Limb Ischemia (CLI), Rutherford Symptom Score of 4,5, or 6. Patients in who arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder.

Sites / Locations

  • Cardiology, PC
  • Northwestern University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

3

Arm Description

Outcomes

Primary Outcome Measures

Safety of Intramuscular administration of CD34-positive cells

Secondary Outcome Measures

Functional improvement

Full Information

First Posted
April 4, 2006
Last Updated
March 30, 2015
Sponsor
Losordo, Douglas, M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT00311805
Brief Title
Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)
Official Title
Injection of Autologous CD34-Positive Stem Cells for Neovascularization and Symptom Relief in Patients With Severe Intermittent Claudication
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2006 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Losordo, Douglas, M.D.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of the study is to determine the safety and possible effectiveness of various doses of autologous (one's own) stem cells, delivered with a needle into the regions of the leg with poor blood flow in patients with blocked leg arteries that results in claudication (pain when walking). Stem cells are primitive cells produced by the bone marrow that can develop into blood cells or other types of cells. In addition to determining whether this new approach is safe, the diagnostic tests may offer preliminary insights into the usefulness of this approach for treating intermittent claudication - the condition where areas in the leg are lacking enough oxygen and blood flow to keep the leg muscle working well, causing pain and cramping upon walking. This study is a double-blind, randomized study to compare CD34-positive stem cells versus a placebo agent (salt water solution known as normal saline). The patient will have a 3:1 chance of their stem cells versus the placebo. Regardless of a patient receiving placebo or treatment, all patients will undergo all of the pre-treatment phases of this study, which includes the stem cell mobilization and apheresis procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease, Severe Intermittent Claudication

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Active Comparator
Arm Title
3
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
Autologous Stem Cells (CD34+)
Intervention Description
Intramuscular Injections
Primary Outcome Measure Information:
Title
Safety of Intramuscular administration of CD34-positive cells
Time Frame
All
Secondary Outcome Measure Information:
Title
Functional improvement
Time Frame
Week 12, Month 6, Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females equal to or greater than 21 years old Patients with infra-inguinal atherosclerosis with a stenosis or occlusion of a major vessel in the affected limb(s) of one or more of the following arteries: superficial femoral, popliteal, or one or more infrapopliteal arteries, which is/are non-reconstructable. Patients with symptoms of Severe Intermittent Claudication in at least 1 lower limb persisting for at least 6 months (Rutherford Class 3). Patients who have a diagnosis of Peripheral Arterial Disease (PAD) in at least 1 lower limb secondary to atherosclerosis, for at least 6 months. Exclusion Criteria: Patients who have had successful aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 3 month preceding screening. Patients with iliac disease amenable to revascularization. Patients judged to be a suitable candidate for surgical or percutaneous revascularization in the limb in which treatment is proposed. Patients with Critical Limb Ischemia (CLI), Rutherford Symptom Score of 4,5, or 6. Patients in who arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas W. Losordo, M.D.
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology, PC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35211
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

We'll reach out to this number within 24 hrs